These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 34154390)

  • 1. Lipid-Lowering Therapy and Hemorrhagic Stroke Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors.
    Sanz-Cuesta BE; Saver JL
    Stroke; 2021 Oct; 52(10):3142-3150. PubMed ID: 34154390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bétrisey S; Haller ML; Efthimiou O; Speierer A; Del Giovane C; Moutzouri E; Blum MR; Aujesky D; Rodondi N; Gencer B
    J Am Heart Assoc; 2024 Feb; 13(4):e030714. PubMed ID: 38323514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
    Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
    Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.
    Tramacere I; Boncoraglio GB; Banzi R; Del Giovane C; Kwag KH; Squizzato A; Moja L
    BMC Med; 2019 Mar; 17(1):67. PubMed ID: 30914063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-Modifying Therapies and Stroke Prevention.
    Hackam DG; Hegele RA
    Curr Neurol Neurosci Rep; 2022 Jul; 22(7):375-382. PubMed ID: 35554824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive Drugs for Secondary Prevention After Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
    Boncoraglio GB; Del Giovane C; Tramacere I
    Stroke; 2021 Jun; 52(6):1974-1982. PubMed ID: 33902303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients.
    Sirimarco G; Labreuche J; Bruckert E; Goldstein LB; Fox KM; Rothwell PM; Amarenco P;
    Stroke; 2014 May; 45(5):1429-36. PubMed ID: 24736236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging agents for the treatment and prevention of stroke: progress in clinical trials.
    Safouris A; Magoufis G; Tsivgoulis G
    Expert Opin Investig Drugs; 2021 Oct; 30(10):1025-1035. PubMed ID: 34555978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Initiation of PCSK9 Inhibitor Therapy Versus Placebo in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Justino GB; Justino LB; Müller ME; Rocha AV; Mazetto A; Cardoso R; Leucker TM
    Am J Cardiol; 2024 Feb; 213():110-118. PubMed ID: 37875235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
    Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
    Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications.
    Navarese EP; Kołodziejczak M; Dimitroulis D; Wolff G; Busch HL; Devito F; Sionis A; Ciccone MM
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):44-53. PubMed ID: 27533061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Statins in the secondary prevention of stroke: New evidence from the SPARCL Study].
    Castilla-Guerra L; Fernández-Moreno Mdel C; López-Chozas JM
    Clin Investig Arterioscler; 2016; 28(4):202-8. PubMed ID: 26150172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation.
    LaFratte C; Peasah SK; Huang Y; Hall D; Patel U; Good CB
    J Am Heart Assoc; 2023 Sep; 12(18):e029707. PubMed ID: 37702065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V; Pereira AC
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deintensification or No Statin Treatment Is Associated With Higher Mortality in Patients With Ischemic Stroke or Transient Ischemic Attack.
    Dearborn-Tomazos JL; Hu X; Bravata DM; Phadke MA; Baye FM; Myers LJ; Concato J; Zillich AJ; Reeves MJ; Sico JJ
    Stroke; 2021 Aug; 52(8):2521-2529. PubMed ID: 34015937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.